What's Happening?
Altruist Biologics, a subsidiary of Innovent Biologics, has launched the Altru-CON platform, a high-concentration formulation technology designed to accelerate the development and commercialization of high-dose biologics. This platform allows for protein
concentrations of up to 200 mg/mL and reduces viscosity by over two-fold, addressing significant technical challenges in biologics manufacturing. The Altru-CON platform utilizes a high-throughput screening approach and an intelligent excipient optimization system, which incorporates more than 30 excipient combinations to maintain low viscosity suitable for subcutaneous administration. This advancement is expected to enhance drug delivery, reduce dosing frequency, and simplify cold chain logistics, ultimately improving manufacturing efficiency and shortening IND submission timelines.
Why It's Important?
The introduction of the Altru-CON platform is significant for the biologics industry, which is moving towards higher drug concentrations and more patient-friendly delivery formats. By addressing technical hurdles such as protein-on-protein interactions and viscosity control, Altru-CON enhances the flexibility of injection volumes and reduces the frequency of dosing. This innovation not only improves the efficiency of drug substance and product manufacturing but also reduces the risks associated with immunogenicity. The platform's ability to support high-concentration biologics from low to ultra-high concentrations with improved stability and viscosity control is crucial for advancing next-generation biologics, potentially benefiting patients with more effective and convenient therapies.
What's Next?
Altruist Biologics plans to continue leveraging the Altru-CON platform to support its partners in accelerating the development of advanced therapies. The company has already supported one approved high-concentration product, two late-stage clinical programs, six early-stage clinical programs, and ten preclinical projects. As the platform gains traction, it is expected to play a pivotal role in the biologics sector, potentially influencing regulatory standards and encouraging further innovation in high-concentration drug formulations.
